Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

FDA approves Fotivda for relapsed or refractory advanced RCC

March 11, 2021

Dosing initiates in first-in-human study of IMP-7068 in advanced solid tumors

March 11, 2021

Novartis identifies new NSD2 inhibitors

March 11, 2021

Bristol Myers Squibb discloses new IRAK-4 inhibitors

March 11, 2021

PI3K inhibitor umbralisib shows clinical activity in patients with indolent non-Hodgkin's lymphoma

March 10, 2021

Artios Pharma describes new POLQ inhibitors

March 10, 2021

Wigen Biomedicine Technology divulges KRAS mutant inhibitors

March 10, 2021

Pirtobrutinib demonstrates safety and efficacy in multiple B-cell malignancies

March 10, 2021

Dovitinib demonstrates promising antitumor activity in preclinical model of osteosarcoma

March 10, 2021

New model for invasive lobular carcinoma points to LOXL1 as a therapeutic target

March 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...